Mounjaro (Tirzepatide) Injection 2.5MG

**Eli Lilly and Company is proud to announce that the U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide) injection for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. The approval of Mounjaro represents the first new class of diabetes medication introduced in nearly a decade.

Mounjaro is the first and only approved once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is a single molecule that targets the body’s receptors for GIP and GLP-1, which are natural incretin hormones. Results from the global phase 3 SURPASS program supported this approval.**